STRATEGIC PLAN



Drug the undruggable; a 5-tier strategy



- define the patient group that will gain benefit
- define the druggable key-players (proteins, proteoforms, protein variants)
- select repurposed drugs based on AI & human synergies
- profile candidates (efficacy, ADMETox)
- identify & validate companion biomarkers



Map inter-individual variability upon xenobiotics profiling



- proteomics-based multi-omics
- artificial-human intelligence workspace -> data mining and curation -> data reliability & reproducibility
- validation; spatial proteomics, single cell and/or exosomal proteomics, photoacoustic-LC-MSn.

- genotype-to-phenotype associations -> clinical interpretome
- monitoring of immunomodulatory mechanisms
- ADMETox profiling for cell- & gene- therapies



Digital Biomarkers

- consumer-generated physiological measures
- consumer-generated behavioral measures
- digital tools

- family health history profiling
- companion biomarkers
- point-of-care testing